DGAP-News: PAION ANNOUNCES INITIATION OF SECOND U.S. PHASE

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
DGAP-News: PAION ANNOUNCES INITIATION OF SECOND U.S. PHASE III CLINICAL TRIAL OF REMIMAZOLAM FOR PROCEDURAL SEDATION DURING BRONCHOSCOPY

DGAP-News: PAION AG / Key word(s): Research Update PAION ANNOUNCES INITIATION OF SECOND U.S. PHASE III CLINICAL TRIAL OF REMIMAZOLAM FOR PROCEDURAL SEDATION DURING BRONCHOSCOPY 08.06.2015 / 14:00 --------------------------------------------------------------------- PAION ANNOUNCES INITIATION OF SECOND U.S. PHASE III CLINICAL TRIAL OF REMIMAZOLAM FOR PROCEDURAL SEDATION DURING BRONCHOSCOPY Aachen, 08 June 2015 - PAION AG, a Specialty Pharma Company (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announced the initiation of the second pivotal U.S. Phase III clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing bronchoscopy. The current trial forms the second pivotal study of the Remimazolam Phase III program. PAION and the U.S. Food and Drug Administration (FDA) have agreed on the remaining development program (indications, size of studies and design). Wolfgang Söhngen, M.D., Ph.D., chief executive officer of PAION AG, said: "The Phase III bronchoscopy study is intended to confirm the efficacy and safety profile of Remimazolam in additional procedural sedation applications with the intention of broadening the target patient population and to achieve a broad label in procedural sedation. Because most patients undergoing bronchoscopy have a pre-existing pulmonary disease, Remimazolam's benign safety profile including its effect on the respiration system is critically important to its success as a sedative for these procedures. During Phase II clinical trials in colonoscopy and upper endoscopy, Remimazolam had an excellent safety profile including respiratory stability and was highly effective in providing sedation resulting in successfully completed procedures." This Phase III clinical trial is a prospective, double-blind, randomized, placebo- and midazolam-controlled, U.S. multicenter study in 460 patients undergoing bronchoscopies. Patients will be randomized to receive Remimazolam, midazolam or placebo in addition to fentanyl to achieve moderate sedation. The primary endpoint is the successful completion of the bronchoscopy procedure with no requirement for an alternative sedative. The completion of patient recruitment is expected in 2016. ### About Remimazolam Remimazolam is an innovative ultra-short-acting general sedative/anesthetic. As a result of its short duration of action and good controllability, it has a preferable efficacy and safety profile relative to other currently marketed anesthesia compounds. Remimazolam's rapid offset is a consequence of its metabolism by tissue esterase enzymes that are widely distributed throughout the body. While the key positioning in conscious sedation will be a low impact on respiratory function it will be cardiovascular stability for general anesthesia. Remimazolam has potential in three indications: - Procedural sedation (Lead indication U.S.) - General anesthesia (Lead indication EU, Japan) - ICU sedation (Phase 2 Japan) Remimazolam is available for licensing outside China, Russia (CIS) Turkey, MENA Region, South Korea and Canada, where the compound is partnered with Yichang Humanwell, R-Pharm, TR-Pharm, Hana Pharm and Pendopharm. About PAION PAION AG is a publicly-listed Specialty Pharma Company headquartered in Aachen, Germany with further sites in Cambridge, UK and New Jersey, US. The company has a track record of developing hospital-based treatments for which there is substantial unmet medical need. PAION's strategy is to participate in the commercialization of Remimazolam and extend its business with a focus on anesthesia/critical care products. Remimazolam is the building block for its future marketing activities. PAION Contact Ralf Penner Director Investor Relations / Public Relations PAION AG Martinstrasse 10-12 52062 Aachen - Germany Phone: +49 241 4453-152 E-mail: r.penner@paion.com www.paion.com Disclaimer: This release contains certain forward-looking statements concerning the future business of PAION AG. These forward-looking statements contained herein are based on the current expectations, estimates and projections of PAION AG's management as of the date of this release. They are subject to a number of assumptions and involve known and unknown risks, uncertainties and other factors. Should actual conditions differ from the Company's assumptions, actual results and actions may differ materially from any future results and developments expressed or implied by such forward-looking statements. Considering the risks, uncertainties and other factors involved, recipients should not rely unreasonably upon these forward-looking statements. PAION AG has no obligation to periodically update any such forward-looking statements to reflect future events or developments. --------------------------------------------------------------------- 08.06.2015 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- Language: English Company: PAION AG Martinstr. 10-12 52062 Aachen Germany Phone: +49 (0)241-4453-0 Fax: +49 (0)241-4453-100 E-mail: info@paion.com Internet: www.paion.com ISIN: DE000A0B65S3 WKN: A0B65S Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of News DGAP News-Service --------------------------------------------------------------------- 364511 08.06.2015

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 28

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 161

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 78

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 343

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 342

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 86

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
MoneyGram and Solflare Boost Crypto Cash-Out Options

Updated Category News Views 24

Crypto Meets Cash: A New Partnership in Money Movement Here's something to chew over your morning joe: MoneyGram's stepping up its game in the crypto world. They're pairing up with Solflare to let folks convert their USDC into hard cash across 170 countries and territories—no fees until New Year's Eve. It's like crypto's getting a passport to the physical world and not...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 207

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading

Top 5 Most Recently Viewed Articles

Mercy Medical Center Nurses Mobilize for Patient Safety Picket

Updated Category News Views 35

Nurses Standing Together for Patient Safety Nurses at Mercy Medical Center are uniting for a cause that affects them profoundly: the safety of their patients and the workplace. With issues surrounding unsafe staffing and deteriorating care conditions, nurses represented by the Massachusetts Nurses Association plan to hold an informational picket. This demonstration is not...

Continue Reading
Massive Merger: Qorvo and Skyworks Unite for Future Innovations

Updated Category News Views 306

Overview of the Strategic Merger In an exciting development in the technology sector, shares of Qorvo, Inc. (NASDAQ: QRVO) and Skyworks Solutions, Inc. (NASDAQ: SWKS) are experiencing a notable surge after announcing their intent to merge. This deal, which values the combined entity at approximately $22 billion, marks a significant step forward in the realm of...

Continue Reading
Oryzon Genomics Announces Corporate Updates for September

Updated Category News Views 178

Oryzon Genomics to Share Updates on Corporate Progress Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a leading clinical-stage biopharmaceutical company dedicated to epigenetic therapies for critical medical needs, is set to present its latest corporate updates at several major international events. These important gatherings scheduled for September will showcase...

Continue Reading
Envision Energy Launches Innovative Energy Storage Solution

Updated Category News Views 363

Introducing the EN 8 Pro: A Revolution in Energy Storage Envision Energy, a leader in sustainable technology, has made a significant breakthrough in energy management with the launch of its EN 8 Pro 8MWh DC Liquid-Cooled Energy Storage System. This innovative setup is set to establish new industry standards in safety, efficiency, and environmental adaptability. Designed...

Continue Reading
Beard Papa's Teams Up for Exciting Zenless Zone Zero Launch

Updated Category News Views 528

Beard Papa's Exciting Flavor Collaboration Begins Beard Papa's, renowned for its delectable cream puffs and irresistible custard fillings, is thrilled to announce a nationwide collaboration with Zenless Zone Zero. This partnership will launch an exciting in-game event that will allow fans to experience the unique flavors inspired by the action-RPG sensation from...

Continue Reading